Showing results (281-290 of 324) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatmentsAlfonso Cortés, José L Casado, Federico Longo, et al.
Frontiers in Neuroanatomy|April 10, 2023
Ex vivo, in situ perfusion protocol for human brain fixation compatible with microscopy, MRI techniques, and anatomical studiesRicardo Insausti, Ana María Insausti, Mónica Muñoz López, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 studyThomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Clinical & Experimental Metastasis|February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV studyOndřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Gut|March 18, 2024
New entity of adult ultra-short coeliac disease: the first international cohort and case-control studySuneil A Raju, Emily A Greenaway, Annalisa Schiepatti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
The Lancet. Global Health|May 13, 2022
City planning policies to support health and sustainability: an international comparison of policy indicators for 25 citiesMelanie Lowe, Deepti Adlakha, James F Sallis, et al.
Pageof 33